AusperBio AHB-137 gains breakthrough status in China for CHB

AusperBio Therapeutics and Ausper Biopharma have received breakthrough therapy designation in China for AHB-137 for CHB.

Jul 12, 2024 - 04:00

AusperBio AHB-137 gains breakthrough status in China for CHB

AusperBio Therapeutics and Ausper Biopharma have received breakthrough therapy designation in China for AHB-137 for CHB.

Read the original article

Tags:

Previous Article

Boehringer Ingelheim plans sustainability work for the long term

Biotech survey highlights where industry can focus for a thriving future

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Reprieve for WuXi as Biosecure vote likely pushed to 2025

Reprieve for WuXi as Biosecure vote likely pushed to 2025

Dec 17, 2024

23andMe breach targeted Chinese, Jewish populations

23andMe breach targeted Chinese, Jewish populations

Jan 30, 2024

Coherus acquires immuno-oncology company Surface

Coherus acquires immuno-oncology company Surface

Sep 11, 2023